2015-03-12T22:19:11-05:00 2014-06-30 911194016 CLARK NUBER PS 10900 NE 4TH STREET SUITE 1700 BELLEVUE WA 98004 990 2013-07-01 911935159 SEATTLE CANCER CARE ALLIANCE SEAT 2062881000 825 EASTLAKE AVENUE EAST PO BOX 19023 SEATTLE WA 981091023 JONATHAN TINGSTAD CHIEF FINANCIAL OFFICER 2062881000 2015-03-12 1 SARA ELIZABETH J HYRE P00235495 4254544919 2015-03-12 2013 2016-03-07 17:11:31Z FRED APPELBAUM MD 1100 FAIRVIEW AVE N SEATTLE WA 98109 637300958 0 X WWW.SEATTLECCA.ORG X 1998 WA SEATTLE CANCER CARE ALLIANCE (SCCA) IS A NATIONAL CANCER INSTITUTE (NCI)(SEE SCHEDULE O) DESIGNATED COMPREHENSIVE CANCER TREATMENT CENTER THAT UNITES THE DOCTORS FROM FRED HUTCHINSON CANCER RESEARCH CENTER, UW MEDICINE, AND SEATTLE CHILDREN'S. OUR GOAL, EVERY DAY, IS TO TURN CANCER PATIENTS INTO CANCER SURVIVORS. OUR PURPOSE IS TO LEAD THE WORLD IN THE PREVENTION AND TREATMENT OF CANCER. 18 17 1390 232 0 0 3643872 2092569 384863259 430480614 4125031 1996124 32170 41875 392664332 434611182 1632418 1301089 0 0 94579014 99764523 43030 21405 21405 269361205 308327052 365615667 409414069 27048665 25197113 440984867 488899365 157922861 170708733 283062006 318190632 X SEATTLE CANCER CARE ALLIANCE, SCCA, IS A PART OF THE FRED HUTCHINSON/UW CANCER CONSORTIUM, THE CONSORTIUM, WHICH IS ONE OF 41 COMPREHENSIVE CANCER CENTERS DESIGNATED BY THE NATIONAL CANCER INSTITUTE (NCI). THE CONSORTIUM'S MEMBERS ARE SCCA, (SEE SCHEDULE O) FRED HUTCHINSON CANCER RESEARCH CENTER, UW MEDICINE, AND SEATTLE CHILDREN'S. THE NCI DESIGNATION GIVES SCCA'S PATIENTS ACCESS TO RECEIVE THE LATEST TAILORED COURSE OF TREATMENTS AND THERAPIES FOR CANCER AND HAVE ACCESS TO NEW DRUGS AND TREATMENTS THAT ARE UNDER INVESTIGATION IN CLINICAL STUDIES ONLY AVAILABLE AT SCCA AND LIMITED SITES AROUND THE COUNTRY. OUR GOAL IS TO TURN CANCER PATIENTS INTO CANCER SURVIVORS. OUR PURPOSE IS TO LEAD THE WORLD IN THE PREVENTION AND TREATMENT OF CANCER. UNITING THE DOCTORS FROM FRED HUTCHINSON CANCER RESEARCH CENTER, UW MEDICINE, AND SEATTLE CHILDREN'S, SCCA IS HOME TO THE WORLD'S BEST SURGEONS, MEDICAL ONCOLOGISTS, RADIATION ONCOLOGISTS, PATHOLOGISTS, AND RADIOLOGISTS. 0 0 310789306 1174703 433371936 SCCA'S FOCUS IS TO SPEED THE TRANSFER OF NEW DIAGNOSTIC AND TREATMENT TECHNIQUES FROM THE RESEARCH SETTING TO PATIENT CARE. THE HIGHLY INTEGRATED APPROACH TO CANCER RESEARCH AND TREATMENT AMONG SCCA PARTNER ORGANIZATIONS SUPPORTS THE FLOW OF SCIENTIFIC INFORMATION AMONG RESEARCHERS, CLINICIANS, AND PATIENTS, THEREBY ACCELERATING THE DEVELOPMENT OF NEW KNOWLEDGE AND TREATMENT OF VARIOUS CANCERS. DURING THE YEAR ENDED JUNE 30, 2014, SCCA TREATED 6,584 NEW PATIENTS WITHIN THE CANCER AND BONE MARROW/STEM CELL TRANSPLANT PROGRAMS. SCCA ALSO HAD 77,177 CLINIC VISITS, 103,888 INFUSION HOURS, 11,987 RADIATION ONCOLOGY TREATMENTS, AND PERFORMED 45,249 IMAGING SCANS.AS PART OF SCCA'S COMMITMENT TO ADVANCING THE STANDARD OF CANCER CARE, IT OFFERS MANY EDUCATIONAL OPPORTUNITIES FOR HEALTH CARE PROFESSIONALS OF ALL KINDS SEEKING THE SPECIALIZED KNOWLEDGE IN ONCOLOGY SETTINGS TO EARN CONTINUING EDUCATION CREDITS. SCCA IS DESIGNATED AS AN INSTRUCTIONAL SITE FOR BACHELOR AND ADVANCED DEGREE CANDIDATES FROM SEVERAL INSTITUTIONS AROUND THE PUGET SOUND AREA. IN ADDITION, SCCA HAS MANY EDUCATIONAL OFFERINGS TO CANCER PATIENTS, CAREGIVERS, THEIR FAMILIES, AND CANCER SURVIVORS. 2987001 126386 2215262 SEATTLE CANCER CARE ALLIANCE HOUSE IS A TEMPORARY MEDICAL HOUSING FACILITY. IT IS AN 80-ROOM FACILITY THAT PROVIDES AN AFFORDABLE HOME FOR CANCER PATIENTS AND THEIR FAMILIES WHO COME TO SEATTLE FOR EXTENDED TREATMENT WITH SCCA. THE SIX-STORY "BUILT GREEN" BUILDING WAS DESIGNED TO ADDRESS PATIENTS' PHYSICAL, EMOTIONAL, AND LOGISTICAL CHALLENGES. SCCA HOUSE IS LOCATED CLOSE TO THE SCCA OUTPATIENT CLINIC AND OFFERS SHUTTLE SERVICE TO THE SCCA CLINIC. THE SCCA HOUSE OFFERS PATIENTS A HOME AWAY FROM HOME WITH WELLNESS AND EXERCISE ROOMS, IN ROOM KITCHENETTES, A LARGE COMMON KITCHEN AND DINING ROOM, RESOURCE CENTER AND LIBRARY, THEATER, EXERCISE ROOM, IN-ROOM, SEPARATE CAREGIVER SLEEPING AREAS, FREE LAUNDRY 24 HRS/DAY, FREE WIRELESS INTERNET ACCESS, SECURE BUILDING, GARAGE AND PARKING, INFECTION CONTROL MEASURES, AS WELL AS A ROOFTOP GARDEN. THE COMMON AREAS SERVE AS MEETING CENTERS FOR OUR COMMUNITY PARTNERS. SCCA HOUSE IS AN EXAMPLE OF SCCA'S COMMITMENT TO THE MISSION OF PROVIDING FAMILY CENTERED PATIENT CARE. -5000000 SCCA PROTON THERAPY, A PROCURE CENTER (CENTER) LOCATED ON UW MEDICINE'S NORTHWEST HOSPITAL & MEDICAL CENTER CAMPUS, OPENED DURING 2013. AN ADVANCED FORM OF RADIATION TREATMENT, PROTON THERAPY CAN BE CALIBRATED WITH GREAT PRECISION TO SELECTIVELY KILL CANCER CELLS. THE CLINICAL BENEFITS PROTON THERAPY OFFERS OVER STANDARD X-RAY TREATMENT FOR CERTAIN TYPES OF CANCER ARE BECOMING INCREASINGLY WELL KNOWN. THE ACCURACY OF THE DELIVERY OF PROTON RADIATION, FOR EXAMPLE, REDUCES DAMAGE TO THE HEALTHY TISSUES AND ORGANS SURROUNDING TUMORS. OTHER BENEFITS INCLUDE FEWER SIDE EFFECTS, INCLUDING A DECREASED RISK OF DEVELOPING SECONDARY TUMORS (CANCERS THAT RESULT FROM RADIATION TREATMENT). SINCE PROTON THERAPY WAS APPROVED BY THE US FOOD AND DRUG ADMINISTRATION TO TREAT PATIENTS IN 1988, THE MEDICAL COMMUNITY HAS CONTINUED TO CONDUCT RESEARCH ON THE USE OF PROTONS IN TREATING DIFFERENT TYPES OF CANCER THROUGH CLINICAL TRIALS. OVER THE YEARS, MANY PATIENTS HAVE VOLUNTEERED TO TAKE PART IN THESE CLINICAL TRIALS TO HELP FIND IMPROVEMENTS IN FIGHTING CANCER WITH PROTON THERAPY. THE CENTER, WITH OUR PARTNER THE UNIVERSITY OF WASHINGTON, IS CURRENTLY PARTICIPATING IN MANY CLINICAL TRIALS. IN OUR QUEST TO LOOK FOR WAYS TO IMPROVE THE LIVES OF PATIENTS WITH CANCER, OUR CENTER WILL PARTICIPATE IN CLINICAL TRIALS TO FURTHER OUR KNOWLEDGE OF THE BENEFITS OF PROTON THERAPY IN MANY TUMOR TYPES. OUR DOCTORS VIEW THE NEW CENTER AS A TREMENDOUS OPPORTUNITY TO TAKE THE LEAD IN ACTIVE CLINICAL INVESTIGATIONS THAT WILL HELP DEFINE THE ROLE OF PROTON THERAPY IN FUTURE CANCER TREATMENT. ONGOING STUDIES CONDUCTED BY SCCA DOCTORS WILL HELP CHART A CLEAR COURSE FOR THE USE OF PROTON RADIATION IN ACHIEVING THE BEST POSSIBLE OUTCOMES IN TREATING CANCER. 313776307 1 1 0 1 0 0 0 0 0 1 1 0 0 0 0 1 1 0 0 0 1 0 0 1 0 0 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 1 146 0 1 1390 1 0 0 0 0 0 0 0 0 0 0 X 18 17 1 0 0 0 1 1 1 1 1 0 1 1 1 1 1 1 1 0 1 1 1 1 AL AK AR CO CT FL HI IL KS KY ME MD MA MI MS NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI MN MO AZ X JONATHAN TINGSTAD 2062881058 825 EASTLAKE AVENUE EAST PO BOX SEATTLE WA 98109 ROBB BAKEMEIER CHAIRMAN 10.00 X X 0 0 0 CARL BEHNKE VICE CHAIR 6.00 X X 0 0 0 RICH MCCUNE TREASURER 1.50 X X 0 0 0 KIMBERLY MCNALLY MN RN SECRETARY 3.00 X X 0 0 0 LISA BRANDENBURG DIRECTOR 1.00 X 0 0 0 MIKE DELMAN DIRECTOR 4.00 X 0 0 0 MARK GROUDINE MD PHD DIRECTOR 2.00 X 0 0 0 JONELLE JOHNSON DIRECTOR 2.00 X 0 0 0 RICH JONES DIRECTOR 3.00 X 0 0 0 ROB MACAULAY DIRECTOR 3.00 X 0 0 0 RUTH MAHAN DIRECTOR 3.00 X 0 0 0 LINDA MATTOX DIRECTOR 1.00 X 0 0 0 SHAN MULLIN DIRECTOR 4.00 X 0 0 0 BROOKS RAGEN DIRECTOR 1.50 X 0 0 0 JOHNESE SPISSO DIRECTOR 5.00 X 0 0 0 BRUDER STAPLETON MD DIRECTOR 1.50 X 0 0 0 MYRA TANITA DIRECTOR 1.50 X 0 0 0 RICHARD YARMUTH DIRECTOR 3.00 X 0 0 0 FRED APPELBAUM MD EXECUTIVE DIRECTOR/PRESIDENT 12.00 X 322262 0 0 NORMAN HUBBARD EXECUTIVE VICE PRESIDENT 55.00 X 575586 0 47950 JONATHAN TINGSTAD VP/CFO 55.00 X 428186 0 52588 MADELINE BUELT VP OPERATIONS/CHIEF NURSE 55.00 X 347742 0 48862 F MARC STEWART MD VP/MEDICAL DIRECTOR 36.00 X 431220 0 0 DAVID ACKERSON VP/CHIEF INFO OFFICER 55.00 X 357691 0 42962 DEBORAH GENTZEN VP/CHIEF STRATEGY OFFICER 55.00 X 388076 0 52364 BARBARA JAGELS VP/QUALITY SAFETY AND VALUE 55.00 X 159144 0 32440 GRETCHEN HANNA DIR. CORPORATE FINANCE 55.00 X 221662 0 34175 CHERYL WYMAN DIR. DIAGNOSIS THERAPY SVCS 55.00 X 220469 0 36527 JOSEPH NORTON DIRECTOR OF FINANCE 55.00 X 214595 0 37765 ZAKARIA RAMADAN-JRADI DIR. CELL THRPY & CLIN LAB 55.00 X 209348 0 36994 ALEANA WAITE DIR. RES INTEG, IMMUNO, CELL THRPY 55.00 X 191029 0 32295 KRISTINE LOGAN DIRECTOR PT ACCESS & FACILITIES 55.00 X 184201 0 24857 SUSAN HAMMOND DIRECTOR PROGRAM MANAGEMENT 55.00 X 182908 0 31299 LINDA LAKE DIR. CLIN INFO SYST & HIM 55.00 X 176590 0 24152 ALPHONSO EMERY DIR. DIVERSITY EFFORTS 55.00 X 171681 0 21969 MOREEN DUDLEY DIR. SUPPORT CARE/SPEC CLINICS 55.00 X 164241 0 27204 CAMILLE RAPACZ DIRECTOR CPI 55.00 X 160100 0 28341 SHARI MCCLURE DIR. MEDICAL STAFF SERVICES 55.00 X 154519 0 21483 MICHELLE HALL DIRECTOR OF IT SERVICES 55.00 X 150492 0 27002 DONNA LENDERMAN REGISTERED NURSE 65.00 X 179992 0 19893 MARGARET OWENS CTP QUALITY SENIOR MANAGER 55.00 X 169237 0 16183 KAREN HOLLOWAY RADIATION ONCOLOGY MANAGER 55.00 X 143372 0 20431 CLAIRE BECK-KEELER DIRECTOR OF MARKETING 55.00 X 142738 0 30203 CECILIA ZAPATA DIR. REGIONAL GLOBAL NETWORK 55.00 X 142533 0 20218 6189614 0 768157 134 0 1 1 UNIVERITY OF WASHINGTON 1959 NE 59TH AVE SUITE 1005 SEATTLE WA 98104 HEALTHCARE, SERVICES, SUPPLIES 200578832 FRED HUTCHINSON CANCER RESEARCH CENTER 1100 FAIRVIEW AVE N SEATTLE WA 98109 ADMIN, SUPPORT, SVCS CONSULT. 19864971 SEATTLE CHILDREN'S HOSPITAL PO BOX 50020 SEATTLE WA 98145 HEALTHCARE SERVICES 12006776 NATIONAL MARROW DONOR PROGRAM 3001 BROADWAY ST NE MINNEAPOLIS MN 55413 MARROW TRANSPLANT SERVICES 10939120 PUGET SOUND BLOOD CENTER 921 TERRY AVENUE SEATTLE WA 98104 BLOOD & TISSUE SERVICES 5391085 79 332116 1760453 342462 2092569 CANCER HOSP/OUTPATIENT 622310 330550508 329970427 580081 MEDICARE/MEDICAID PMTS 923130 100939700 100939700 PATIENT HOUSING 624221 2215262 2215262 INTERAFFILIATE AGMTS 900099 1775144 450830 1324314 SCCA PROTON THERAPY 900099 -5000000 -5000000 430480614 5702840 5702840 909 909 198470524 77031 201625102 630078 -3154578 -553047 -3707625 -3707625 369887 434596 -64709 -64709 EDUCATIONAL EVENTS 923110 106584 106584 106584 434611182 433682803 0 -1164190 X 581788 581788 719301 719301 5485059 1847337 3637722 74626928 48017361 26609567 4375756 2884235 1491521 8926348 5610104 3316244 6350432 3837247 2513185 58306202 29770688 28535514 1978759 1978759 386874 386874 1214765 1214765 21405 21405 564656 564656 77991071 75736154 2254917 3046849 3016975 29874 7622255 4460670 3161585 4221819 676452 3545367 -85920 -85920 6420738 907291 5513447 545058 103922 441136 893602 83225 810377 6344972 6344972 15915064 8059478 7855586 897543 357568 539975 MEDICAL SUPPLIES 105521317 105382866 138451 BUSINESS TAXES 14057758 13751062 306696 BAD DEBT 1682807 1682807 DUES & SUBSCRIPTIONS 540822 6537 534285 260041 24187 235854 409414069 313776307 95616357 21405 14086166 13844686 34432421 32538243 53184873 55057922 3719669 5534493 2759621 3309820 212033137 102948340 109336520 109084797 196146678 244586521 5000000 0 12287624 11046520 10031295 13896363 440984867 488899365 55250019 69801762 230664 229162 102442178 100677809 157922861 170708733 X 280810445 315816153 1365972 1488890 885589 885589 283062006 318190632 440984867 488899365 X 25197113 9986145 -54632 X 0 1 X 1 0 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 1 0 0 1 0 1 1000000 1 170151 0 1 51532 1221683 0 PART II-B, LINE 1: LINE 1B: SCCA TESTIFIED IN OLYMPIA ON THE IMPACT OF THE HEALTHCARE INSURANCE EXCHANGE COVERAGE OFFERINGS AND ITS EFFECT TO LIMIT CANCER PATIENTS' ACCESS TO HEALTHCARE OFFERED BY CANCER CENTERS. SCCA URGED THE OFFICE OF INSURANCE TO REVIEW ITS RULES ON THE EXCLUSION OF SPECIFIC HOSPITALS. LINE 1E: SCCA WROTE A LETTER TO THE COMMUNITY URGING PEOPLE TO CHECK WITH THEIR PROVIDER TO VERIFY ACCESS TO SCCA. THE LETTER WAS WRITTEN IN-HOUSE BY NORMAN HUBBARD, EXECUTIVE VICE PRESIDENT, WITH THE HELP OF INDEPENDENT CONSULTANTS. SCCA ALSO URGED THE COMMUNITY TO CONTACT THE OFFICE OF INSURANCE COMMISSION TO ADDRESS QUESTIONS OR CONCERNS OF THEIR COVERAGE OBTAINED THROUGH THE WA STATE HEALTHCARE EXCHANGE. LINE 1F: SCCA SUPPORTED A BALLOT COMMITTEE, UNITE TO FIGHT CANCER, BOTH DIRECTLY AND INDIRECTLY. THE BALLOT COMMITTEE WAS FORMED TO PUT A STATE-WIDE INITIATIVE ON THE FALL 2014 VOTING BALLOT. THE GOAL OF THE INITIATIVE WAS TO CREATE A DEDICATED FUND THROUGH AN INCREASE IN THE TOBACCO TAX THAT SUPPORTED CANCER RESEARCH, PREVENTION, AND TREATMENT. EXPENDITURES WERE MADE DIRECTLY TO UNITE TO FIGHT CANCER OF $500,000 AND INDIRECTLY THROUGH FRED HUTCHINSON CANCER RESEARCH CENTER OF $500,000. LINE 1G: COMPENSATION PAID TO HIRED LOBBYISTS TO MONITOR AND REVIEW LEGISLATION AT THE LOCAL, STATE, AND FEDERAL LEVELS. LINE 1I: SCCA EMPLOYEES' DIRECT CONTACT WITH LEGISLATORS ON SUBJECT MATTER IMPACTING SCCA = $6,918 LINE 1I: WASHINGTON STATE HOSPITAL ASSOCIATION REPRESENTS MEMBER INTERESTS ON THE LOCAL AND STATE LEVEL. THIS AMOUNT REFLECTS DUES ALLOCATED TO LEGISLATIVE EFFORTS = $28,614 LINE 1I: ALLIANCE OF DEDICATED CANCER CENTERS REPRESENTS MEMBER INTERESTS AT THE NATIONAL LEVEL. AMOUNT EXPENDED = $16,000 906178 129324 44492 3808 987202 892849 36992 20455 3208 906178 900365 7260 14776 892849 800371 112671 12677 900365 757066 43305 800371 0.00000 0.89710 0.10290 0 0 2217938 2217938 122881161 49917657 72963504 7495778 1952850 5542928 71235870 46882482 24353388 8202390 4195351 4007039 109084797 X 443161000 9986146 -783246 9202900 433958100 564656 88426 653082 434611182 408155000 987644 987644 407167356 564656 1682057 2246713 409414069 PART V, LINE 4: INCOME FROM PERMANENTLY RESTRICTED ENDOWMENT FUNDS IS USED FOR THE PURPOSE OF PROVIDING UNCOMPENSATED PATIENT CARE. PART X, LINE 2: SCCA HAS OBTAINED A DETERMINATION LETTER FROM THE INTERNAL REVENUE SERVICE INDICATING THAT IT IS EXEMPT FROM FEDERAL INCOME TAX UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE, EXCEPT FOR UNRELATED BUSINESS INCOME TAX. SCCA RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT OF BEING SUSTAINED. RECOGNIZED INCOME TAX POSITIONS ARE MEASURED AT THE LARGEST AMOUNT THAT IS GREATER THAN 50% LIKELY OF BEING REALIZED. CHANGES IN RECOGNITION OR MEASUREMENT ARE REFLECTED IN THE PERIOD IN WHICH THE CHANGE IN JUDGMENT OCCURS. PART XI, LINE 2D - OTHER ADJUSTMENTS: BAD DEBT EXPENSE -1,682,807. IMPAIRMENT LOSS -54,632. RESTRICTED REVENUES RELEASED 953,153. ROUNDING 1,040. PART XI, LINE 4B - OTHER ADJUSTMENTS: GAIN/LOSS ON DISPOSAL OF FIXED ASSETS -553,048. COST OF GOODS SOLD REPORTED ON PART VIII -434,596. RESTRICTED REVENUES RELEASED 995,042. UNREALIZED GAIN/LOSS ON RESTRICTED ASSETS 81,028. PART XII, LINE 2D - OTHER ADJUSTMENTS: GAIN/LOSS ON DISPOSAL OF FIXED ASSETS 553,048. COST OF GOODS SOLD REPORTED ON PART VIII 434,596. PART XII, LINE 4B - OTHER ADJUSTMENTS: BAD DEBT EXPENSE 1,682,807. ROUNDING -750. EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 PROGRAM SERVICE BLOOD/BLOOD PATHOGENS 233324 MIDDLE EAST AND NORTH AFRICA 0 0 PROGRAM SERVICE BLOOD/BLOOD PATHOGENS 38350 NORTH AMERICA 0 0 PROGRAM SERVICE BLOOD/BLOOD PATHOGENS 670 NORTH AMERICA 0 0 PROGRAM SERVICE TECHNOLOGY SUPPLIES 44118 NORTH AMERICA 0 0 FUNDRAISING N/A 1500 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICE BLOOD/BLOOD PATHOGENS 1775 SOUTH AMERICA 0 0 PROGRAM SERVICE BLOOD/BLOOD PATHOGENS 370 0 0 0 0 0 0 320107 0 320107 0 0 0 0 0 0 PART I, LINE 2: SCCA SOURCES PERIPHERAL BLOOD STEM CELLS, BONE MARROW, AND CORD BLOOD FROM ALL OVER THE WORLD TO TREAT TRANSPLANT PATIENTS. IN DELIVERING STEM CELL TRANSPLANT SERVICES, SCCA SEEKS OUT THE MOST APPROPRIATE DONOR BASED ON CRITERIA OF HUMAN LEUKOCYTE ANTIGEN MATCH AND OTHER PERTINENT DONOR CRITERIA. HAVING THE CLOSEST POSSIBLE BONE MARROW DONOR MATCH IS CRUCIAL TO THE SURVIVAL OF THE PATIENT. ALSO, SOME OF THE FOREIGN DONOR ORGANIZATIONS HAVE HIGHER LEVELS OF TYPING ON THEIR DONOR WHICH REDUCED PATIENT COSTS. PART I, LINE 3: METHOD OF ACCOUNTING USED TO ACCOUNT FOR FOREIGN EXPENDITURES: ACCRUAL. X X X X X 1 FRED HUTCHINSON CANCER RESEARCH CENTER 1100 FAIRVIEW AVENUE NORTH SEATTLE WA 98109 DEVELOPMENT, GIFT PROCESSING 0 0 21405 -21405 21405 -21405 AL AK AR CO CT FL HI IL KS KY ME MD MA MI MN MS NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI AZ MO 1 1 X 1 X 1 X 1 1 0 1 1 3939892 3939892 0.00950 39999611 17423619 22575992 0.05470 697203 785955 -88752 0.00000 44636706 18209574 26427132 0.06420 6188649 2316684 3871965 0.00940 3982816 35820 3946996 0.00960 331822 47309 284513 0.00070 6270458 588367 5682091 0.01380 769489 769489 0.00190 17543234 2988180 14555054 0.03540 62179940 21197754 40982186 0.09960 1 1682807 68617537 76700594 -8083057 X 1 1 1 1 SEATTLE CANCER CARE ALLIANCE 1959 NE PACIFIC STREET SEATTLE WA 98195 WWW.SEATTLECCA.ORG HAC.FS.0000 X X ACUTE CARE HOSPITAL SEATTLE CANCER CARE ALLIANCE 1 1 X X X X X X X X X 12 1 0 1 X WWW.SEATTLECCA.ORG X X X X X X X X 0 0 1 1 200.000000000000 1 300.000000000000 1 X X X X X X X 1 1 X X 1 1 X X X X 0 X X X 0 0 SEATTLE CANCER CARE ALLIANCE PART V, SECTION B, LINE 3: SCCA CONDUCTED AN ONLINE SURVEY TO COLLECT INFORMATION ABOUT CANCER-RELATED HEALTH CONCERNS. THE SURVEY WAS SENT TO 58 INDIVIDUALS AND ORGANIZATIONS REPRESENTING HEALTHCARE PROVIDERS, COMMUNITY PARTNERS, CANCER SUPPORTIVE SERVICES, FOUNDATIONS, MEDIA, OTHER EDUCATIONAL PROVIDERS, COMMUNITY AND BUSINESS LEADERS, AND CANCER SURVIVORS FROM PREDOMINATELY KING, PIERCE, AND SNOHOMISH COUNTIES. IN ADDITION, SCCA IS PARTICIPATING IN A KING COUNTY-WIDE GROUP CALLED THE KING COUNTY COMMUNITY HEALTH NEEDS ASSESSMENT (KC CHNA) COLLABORATIVE. THIS GROUP REVIEWED SCCA'S COMMUNITY HEALTH NEEDS ASSESSMENT (CHNA) AND MADE SUGGESTIONS TO IMPROVE IT. THE COLLABORATION EFFORT IS LED BY THE SEATTLE KING COUNTY DEPARTMENT OF PUBLIC HEALTH AND INCLUDES MOST OF THE HOSPITALS IN KING COUNTY. THE PURPOSE OF THE KC CHNA COLLABORATIVE IS TOINSTITUTIONALIZE A COLLABORATIVE APPROACH TO CONDUCT A COMPREHENSIVE COMMUNITY HEALTH NEEDS ASSESSMENT FOR KING COUNTY AND TO IDENTIFY OPPORTUNITIES FOR THE DEVELOPMENT AND IMPLEMENTATION OF COLLECTIVE, DATA-DRIVEN, IMPLEMENTATION STRATEGIES OVER THE NEXT THREE YEARS. SEATTLE CANCER CARE ALLIANCE PART V, SECTION B, LINE 5D: DURING FY13, SCCA DISTRIBUTED ITS CHNA AND SURVEY RESULTS TO ITS PATIENT AND FAMILY ADVISORY GROUP. THE SCCA PATIENT AND FAMILY ADVISORY GROUP IS MADE UP OF PAST AND PRESENT PATIENTS AND THEIR FAMILY MEMBERS. SCCA ALSO DISTRIBUTED ITS CHNA TO THE KING COUNTY CHNA COLLABORATIVE, WHICH IS A GROUP OF HOSPITALS FORMED TO WORK TOGETHER ON THE HEALTHIER HOSPITALS INITIATIVE. SCCA'S CHNA CONTINUES TO BE POSTED ON OUR WEBSITE AT WWW.SEATTLECCA.ORG/SCCA-COMMUNITY-HEALTH-NEEDS-ASSESSMENT.CFM SEATTLE CANCER CARE ALLIANCE PART V, SECTION B, LINE 7: THE CHNA PROCESS IDENTIFIED THAT THE INCIDENCE RATE OF CANCER CONTINUES TO GROW AND CANCER IS A LEADING CAUSE OF DEATH IN KING, SNOHOMISH AND PIERCE COUNTIES. REDUCING THE INCIDENCE RATE OF CANCER IS THOUGHT TO OCCUR THROUGH NEW TREATMENTS, TECHNOLOGIES, AND DRUG THERAPIES AS WELL AS BEHAVIOR MODIFICATION AND EARLY DETECTION THROUGH SCREENING. SOME SCCA COMMUNITIES HAVE BARRIERS TO ACCESS, APPROPRIATE HEALTH SERVICES, AND PREVENTION RESOURCES. SCCA HAS IDENTIFIED OPPORTUNITIES FOR OUTREACH AND PREVENTATIVE ACTIVITIES FOR THESE COMMUNITIES AS PART OF ITS CHNA GOALS. BECAUSE OF CONSTRAINED RESOURCES, SCCA IS NOT SPECIFICALLY TARGETING THE FOLLOWING COMMUNITIES: 1) YOUNG ADULTS (THOSE OF 18 YEARS AND YOUNGER) WHO HAVE SIGNIFICANTLY LOWER CANCER RATES; 2) LESBIAN, GAY, BISEXUAL, TRANSGENDER (LBGT) COMMUNITY; 3) HEALTHCARE FOR MALESHOWEVER, SCCA CREATED SEVERAL ACTIVITIES TO ENGAGE WITH THESE COMMUNITIES AND PROVIDE PREVENTION AND SCREENING INFORMATION. SEATTLE CANCER CARE ALLIANCE PART V, SECTION B, LINE 19D: SCCA DOES NOT OPERATE AN EMERGENCY ROOM FACILITY. SCCA HAS PROCEDURES IN PLACE WHEN A PATIENT ENTERS INTO AN EMERGENT CONDITION TO STABILIZE THE PATIENT AND MOVE THEM TO AN APPROPRIATE EMERGENCY FACILITY. SCCA STABILIZES THE PATIENT WITHOUT DISCRIMINATION AND ELIGIBILITY TO PAY. SEATTLE CANCER CARE ALLIANCE PART V, SECTION B, LINE 20D: TO DETERMINE THE MAXIMUM AMOUNT THAT CAN BE CHARGED TO FAP-ELIGIBLE INDIVIDUALS, SCCA USES THE REMAINING FAP PERCENTAGE MULTIPLIED BY THE GROSS CHARGES. IF THE PATIENT IS DEEMED FAP ELIGIBLE FOR 60%, THE AMOUNT BILLED TO THE ELIGIBLE PATIENT IS 40% MULTIPLIED BY THEIR GROSS BILLED CHARGES. 5 SEATTLE CANCER CARE ALLIANCE 825 EASTLAKE AVENUE E SEATTLE WA 98109 HOSPITAL BASED OUTPATIENT CLINIC SCCA AT EVERGREEN HEALTH 12040 NE 128TH STREET KIRKLAND WA 98034 HOSPITAL BASED OUTPATIENT CLINIC SEATTLE CANCER CARE ALLIANCE HOUSE 207 PONTIUS AVENUE N SEATTLE WA 98109 TEMPORARY MEDICAL HOUSING FACILITY SCCA NW HSPTL RADIATION ONCOLOGY CLNC 1560 N 115TH ST - SUITE G-16B SEATTLE WA 981338498 HOSPITAL BASED OUTPATIENT CLINIC SCCA PROTON THERAPY A PROCURE CENTER 1570 N 115TH STREET SEATTLE WA 98133 OUTPATIENT CLINIC PART I, LINE 3C: IN ACCORDANCE WITH WAC 246-453-040 AND SUBJECT TO SCCA FINANCIAL RESOURCES, PATIENTS WILL BE ELIGIBLE TO BE CONSIDERED FOR CHARITY CARE IF THEY SUBMIT THE NECESSARY APPLICATION AND IF THE PARTY RESPONSIBLE FOR PAYMENT HAS A FAMILY INCOME AT OR BELOW 300% OF THE FEDERAL POVERTY STANDARD AS ADJUSTED FOR FAMILY SIZE. IF THE PARTY RESPONSIBLE FOR PAYMENT HAS A FAMILY INCOME AT OR BELOW 200% OF THE FEDERAL POVERTY STANDARD AS ADJUSTED FOR FAMILY SIZE, THE PATIENT WILL BE ELIGIBLE FOR CHARITY CARE IN THE AMOUNT EQUAL TO THE UNPAID BALANCE REMAINING AFTER ALL SOURCES OF THIRD PARTY COVERAGE AND SPONSORSHIP HAVE BEEN EXHAUSTED. IF THE PARTY RESPONSIBLE FOR PAYMENT HAS A FAMILY INCOME BETWEEN 200% AND 300% OF THE FEDERAL POVERTY STANDARD AS ADJUSTED FOR FAMILY SIZE, THE PATIENT WILL BE ELIGIBLE FOR CHARITY CARE BASED ON A SLIDING FEE SCALE FOR THE UNPAID BALANCE REMAINING AFTER ALL SOURCES OF THIRD PARTY COVERAGE AND SPONSORSHIP HAVE BEEN EXHAUSTED. RESPONSIBLE PARTIES WHOSE INCOME EXCEEDS 300% OF THE FEDERAL POVERTY STANDARD AS ADJUSTED FOR FAMILY SIZE BUT WHO HAVE INCURRED CATASTROPHIC ACCOUNT BALANCES AFTER ALL SOURCES OF THIRD PARTY COVERAGE AND SPONSORSHIP WILL BE CONSIDERED FOR CHARITY CARE ON A CASE BY CASE BASIS. PART I, LINE 6A: SCCA COMPLETED AN ANNUAL REPORT FOR FY14 AND IT INCLUDES THE COMMUNITY BENEFIT REPORT INFORMATION. IT IS MADE AVAILABLE TO THE PUBLIC AT THE FRONT DESK AND ON OUR WEBSITE. SCCA'S COMMUNITY BENEFIT INFORMATION IS NOT DISCLOSED IN A REPORT PREPARED BY A RELATED ORGANIZATION. PART I, LINE 7: SCCA UTILIZED WORKSHEET 2 TO ARRIVE AT A COST TO CHARGE RATIO FOR COMPLETING LINE 7. PART I, LINE 7G: THERE ARE NO PHYSICIAN CLINIC EXPENSES INCLUDED. SCCA IS REPORTING AS A COMMUNITY BENEFIT NUTRITIONAL THERAPY SERVICES AS A SUBSIDIZED HEALTH SERVICE.SCCA PROVIDES AMBULATORY ONCOLOGY MEDICAL NUTRITION THERAPY SERVICES FOR ALL PATIENTS. SCCA EMPLOYS HIGHLY TRAINED, ONCOLOGY CERTIFIED DIETITIANS TO TREAT PATIENTS THROUGHOUT THE CANCER SPECTRUM-PREVENTION, ACTIVE TREATMENT, SURVIVORSHIP, AND PALLIATIVE CARE. THE NUTRITION SERVICES PROVIDED AS OF JANUARY 2012 WERE NO LONGER COVERED BY INSURANCE OR MEDICARE. THE SERVICE PROVIDED WOULD NOT BE AVAILABLE IN THE GENERAL COMMUNITY. BECAUSE PATIENTS UNDERGOING TRANSPLANTATION AND CANCER TREATMENTS SUFFER HIGH NUTRITION ACUITY REQUIRING SPECIALIZED KNOWLEDGE FOR EVALUATION AND TREATMENT, SCCA CONTINUES TO PROVIDE THE CARE. PART I, LN 7 COL(F): BAD DEBT EXPENSE INCLUDED IN FORM 990, PART IX IS $1,682,807. IT WAS SUBTRACTED UTILIZING WORKSHEET 1 FROM THE TOTAL ON FORM 990, PART IX TO ARRIVE AT THE DENOMINATOR USED TO CALCULATE THIS COLUMN. PART III, LINE 2: DISCOUNTS ON ACCOUNTS PRIOR TO BAD DEBT STATUS: FOR A PATIENT WHO HAS INSURANCE, CONTRACTUAL ADJUSTMENTS ARE APPLIED TO THE ACCOUNT BASED ON THE INSURANCE COMPANY CONTRACT IN FORCE. THE REMAINING SELF-PAY AMOUNTS ARE NOT FURTHER ADJUSTED. FOR A PATIENT WITH NO INSURANCE, A 10% DISCOUNT IS APPLIED AT TIME OF SERVICE. NO OTHER SPECIFIC DISCOUNTS ARE MADE TO PATIENT ACCOUNTS. AMOUNTS WRITTEN OFF TO BAD DEBT EXPENSE REPRESENT THE UNPAID BALANCE AFTER INSURANCE CONTRACTUAL ADJUSTMENT OR SELF PAY DISCOUNT AND ANY PAYMENTS RECEIVED. ONCE AN ACCOUNT IS IN BAD DEBT STATUS, ANY PAYMENTS RECEIVED ON A PATIENT ACCOUNT CONTINUE TO REDUCE THE OUTSTANDING PATIENT ACCOUNT LIABILITY.ESTIMATED AMOUNT FOR PATIENTS WHO "WOULD QUALIFY" FOR FINANCIAL ASSISTANCE:SCCA IDENTIFIES PATIENTS ELIGIBLE FOR FINANCIAL ASSISTANCE AND THE ACCOUNT IS DESIGNATED AS FINANCIAL ASSISTANCE WITHIN THE PATIENT ACCOUNTING SYSTEM. ALL OTHER ACCOUNTS ARE EVALUATED OVER A PERIOD OF TIME THROUGH A SERIES OF CRITERIA BEFORE DESIGNATION AS BAD DEBT. BECAUSE SCCA IS A SPECIALTY HOSPITAL TREATING CANCER PATIENTS, SCCA MAKES EVERY EFFORT IN COMMUNICATING WITH OUR PATIENTS THE PROGRAMS AND FINANCIAL ASSISTANCE POLICIES AVAILABLE TO ITS PATIENT POPULATION BEFORE, DURING, AND AFTER TREATMENT IS RECEIVED. PART III, LINE 3: PART III LINE 3 IS BLANK FOR SCCA. COMMUNITY BENEFIT: SCCA BELIEVES THAT BAD DEBT EXPENSE SHOULD BE INCLUDIBLE IN THE CALCULATION OF THE COMMUNITY BENEFIT. SCCA PROVIDED TREATMENT TO THOSE PATIENTS UNABLE TO PAY THEIR BILL. IF SCCA DID NOT TREAT THESE PATIENTS, THEY WOULD BE TREATED BY SOMEONE ELSE IN THE COMMUNITY OR THROUGH A GOVERNMENTAL UNIT. PART III, LINE 4: FOR PATIENTS THAT DO NOT QUALIFY FOR CHARITY CARE, SCCA RECOGNIZES REVENUE ON THE BASIS OF ITS STANDARD RATES FOR SERVICES PROVIDED (OR ON THE BASIS OF DISCOUNTED RATES, IF NEGOTIATED OR PROVIDED BY POLICY). ON THE BASIS OF HISTORICAL EXPERIENCE, A PORTION OF SCCA'S PATIENTS WILL BE UNABLE OR UNWILLING TO PAY FOR THE SERVICES PROVIDED. THUS, SCCA RECORDS A PROVISION FOR BAD DEBTS RELATED TO PATIENTS IN THE PERIOD THE SERVICES ARE PROVIDED. PART III, LINE 8: SCCA COMPLETED LINE 6 USING THE ALLOWABLE COSTS FROM THE AS-FILED MEDICARE COST REPORT FOR FY14. THE METHODOLOGY USED TO COMPLETE THE MEDICARE COST REPORT WAS BASED ON THE CMS PROVIDER REIMBURSEMENT MANUAL PUB 15.SCCA CONSIDERS THE SHORTFALL ON MEDICARE SERVICES TO BE 100% COMMUNITY BENEFIT. HAD SCCA NOT DELIVERED THE SERVICES, THE SERVICES AND FINANCIAL LOSS WOULD FALL TO ANOTHER COMMUNITY HOSPITAL. PART III, LINE 9B: PATIENTS WHO HAVE BEEN APPROVED FOR 100% CHARITY ARE REMOVED FROM THE COLLECTIONS WORKFLOW SO THEIR ACCOUNTS WILL NOT BE SENT TO COLLECTIONS. PATIENTS WHO HAVE BEEN AWARDED PARTIAL CHARITY (40% OR 60%) MAY BE SENT TO COLLECTIONS IF THE REMAINING PATIENT BALANCES ARE NOT PAID OR ARRANGEMENTS MADE WITHIN 91 DAYS OF THE FIRST BILLING CYCLE. PART VI, LINE 2: SCCA IS A SPECIALTY HOSPITAL AND OUTPATIENT CLINIC DEDICATED TO PROVIDING STATE-OF-THE-ART PATIENT AND FAMILY CENTERED CARE; SUPPORTING THE CONDUCT OF CANCER CLINICAL RESEARCH AND EDUCATION; ENHANCING ACCESS TO IMPROVED CANCER INTERVENTIONS; AND ADVANCING THE STANDARD OF CANCER CARE, REGIONALLY AND BEYOND. IT BRINGS TOGETHER THE PHYSICIANS FROM FRED HUTCHINSON CANCER RESEARCH CENTER, UW MEDICINE, AND SEATTLE CHILDREN'S IN A WORLD-CLASS TREATMENT CENTER. OUR NEEDS ASSESSMENT STRATEGY IS TO ANALYZE WHERE AND WHAT TYPE OF CANCER IS OCCURRING, DETERMINE WHERE COMPELLING SCIENCE EXISTS, AND MAKE INVESTMENTS TO GROW THESE PROGRAMS. SCCA IN CONJUNCTION WITH FRED HUTCHINSON CANCER RESEARCH CENTER, UW MEDICINE, AND SEATTLE CHILDREN'S REVIEWS THE OCCURRENCE RATES IN THE TYPES OF CANCERS IN COMPARISON TO WHERE RESEARCH DOES NOT EXIST AND MAKES STRATEGIC INVESTMENTS TO DEVELOP SCIENCE, BREAKTHROUGHS, AND TREATMENTS IN AREAS OF CANCER NOT BEING PURSUED BY OTHERS. WITH THE COMBINED EFFORTS OF ALL THREE INSTITUTIONS, STATE-OF-THE-ART RESEARCH IS CONDUCTED AND SHARED WITH THE COMMUNITY.SCCA COMPLETED A FORMAL COMMUNITY HEALTH NEEDS ASSESSMENT (CHNA) PROCESS THAT IS IN COMPLIANCE WITH THE PATIENT PROTECTION ACT AND INTERNAL REVENUE CODE SECTION 501(R). SCCA FOCUSED IN ON THE STATE OF WASHINGTON AND THE IMPACT OF CANCER, IDENTIFYING THE LEADING CAUSES OF DEATH FROM CANCER. SCCA DEFINED ITS COMMUNITY IN ITS CHNA PROCESS TO BE THE THREE SURROUNDING COUNTIES: KING, PIERCE, AND SNOHOMISH COUNTIES. A STUDY OF THE DEMOGRAPHICS OF THE THREE COUNTIES BY GENDER AND ETHNICITY AS COMPARED TO THE SCCA PATIENT POPULATION WAS ANALYZED. THE LEADING CAUSES OF DEATH IN THE THREE COUNTY AREA VERSUS WASHINGTON STATE WERE REVIEWED. THIS ANALYSIS IDENTIFIED CANCER AS THE LEADING CAUSE OF DEATH. FURTHER ANALYSIS WAS COMPLETED LOOKING AT THE TYPES OF CANCER CAUSING MORTALITY. THE NUMBER ONE CAUSE OF DEATH IN WASHINGTON STATE AND KING, SNOHOMISH, AND PIERCE COUNTIES WAS IDENTIFIED TO BE LUNG CANCER, FOLLOWED BY PROSTATE, BREAST, COLORECTAL, AND PANCREAS CANCERS. AS PART OF THE CHNA PROCESS, SCCA LOOKED AT PREVENTION AND SCREENING AND THE CHRONIC DISEASE RISK FACTORS. SCCA REVIEWED ITS PROGRAMS ADDRESSING COMMUNITY NEED AND IDENTIFIED AREAS TO FOCUS ON TO HELP CLOSE THE GAP. SCCA IS IMPLEMENTING TARGETED OUTREACH AND EDUCATIONAL PROGRAMS TO PROVIDE RESOURCE INFORMATION, EDUCATION, AND PREVENTATIVE HEALTH MESSAGES THAT ARE CULTURALLY AND LINGUISTICALLY APPROPRIATE. PART VI, LINE 3: EACH PATIENT ENTERING INTO THE SCCA CLINIC IS GIVEN A BROCHURE DESCRIBING THE FINANCIAL PROGRAMS AVAILABLE WITH THE CONTACT INFORMATION. A FINANCIAL COORDINATOR IS AVAILABLE FREE OF CHARGE TO HELP PATIENTS SIFT THROUGH THE INFORMATION AND HELP COMPLETE THE NECESSARY PAPERWORK TO APPLY FOR ASSISTANCE. INTERPRETER SERVICES ARE AVAILABLE IF NEEDED TO HELP. PART VI, LINE 4: SCCA IS LOCATED IN SEATTLE, WA. THE PATIENT POPULATION UTILIZING THE SERVICES OF SCCA ARE PRIMARILY LOCATED IN THE PACIFIC NORTHWEST; HOWEVER, SCCA HAS PATIENTS FROM ALL OVER WORLD. SCCA IS COMMITTED TO PROVIDING STATE-OF-THE-ART, PATIENT AND FAMILY CENTERED CARE, SUPPORTING THE CONDUCT OF CANCER CLINICAL RESEARCH AND EDUCATION, ENHANCING ACCESS TO IMPROVED CANCER INTERVENTIONS, AND ADVANCING THE STANDARD OF CANCER CARE REGIONALLY AND NATIONALLY.THE REGIONAL POPULATION ESTIMATE FOR THE STATES COMPRISING THE PACIFIC NORTHWEST (WA, OR, ID, MT, AK) ACCORDING TO THE US CENSUS BUREAU FOR 2013 IS 14,263,904.THE SCCA NETWORK PROGRAM INCLUDES NINE COMMUNITY CANCER CENTER AFFILIATES IN WASHINGTON, ALASKA, AND MONTANA. THE AFFILIATIONS ARE WITH COMMUNITY CANCER CENTERS AND PROVIDE ACCESS TO RESOURCES AND THERAPIES FOR THEIR PATIENTS, WHICH INCLUDE THE MEDICALLY UNDERSERVED AREA (MUA) POPULATIONS. THE MUA PATIENT POPULATION RECEIVES THE BENEFIT OF SCCA'S EXPERTISE WITHOUT NEEDING TO LEAVE HOME. THE LOCAL GEOGRAPHICAL AREA SCCA RESIDES IN CONSISTS OF KING, SNOHOMISH, AND PIERCE COUNTIES. THE METROPOLITAN AREA POPULATION ESTIMATE ACCORDING TO THE US CENSUS BUREAU FOR 2013 IS 3,610,105 FOR THE THREE COUNTIES. KING, SNOHOMISH, AND PIERCE COUNTIES ALL HAVE FEDERALLY-DESIGNATED MEDICALLY UNDERSERVED COMMUNITIES. KING COUNTY HAS SIX PROVIDERS DESIGNATED AS FEDERALLY QUALIFIED HEALTH CENTERS (FQHC) WITH TWENTY-NINE OPERATING MEDICAL SERVICES SITES, SNOHOMISH COUNTY HAS TWO FQHC DESIGNATED PROVIDERS WITH FIVE OPERATING MEDICAL SERVICES SITES, AND PIERCE COUNTY HAS TWO FQHC DESIGNATED PROVIDERS WITH TEN OPERATING MEDICAL SERVICES SITES. PIERCE COUNTY IS CONSIDERED A MEDICALLY UNDERSERVED COUNTY BY THE WASHINGTON STATE DEPARTMENT OF PUBLIC HEALTH.SCCA HAS DIRECT RELATIONSHIPS WITH FEDERALLY QUALIFIED HEALTH CENTERS THAT ARE LOCATED IN THE MUAS IN THE KING, SNOHOMISH, AND PIERCE COUNTIES OF WASHINGTON. PUBLIC HEALTH SEATTLE KING COUNTY (PHSKC) AND SEA MAR HAVE SPECIFIC CONTRACTS WITH SCCA AS PART OF OUR OUTREACH SERVICES TO PROVIDE PREVENTIVE HEALTH SCREENINGS AND REACH THE LOCAL UNDERSERVED COMMUNITIES.THE SCCA'S RELATIONSHIP WITH PHSKC IS PART OF THE WASHINGTON BREAST, CERVICAL, AND COLON HEALTH PROGRAM (WBCCHP). THE PURPOSE OF WBCCHP IS TO REDUCE MORTALITY AND MORBIDITY FROM BREAST, CERVICAL, AND COLORECTAL CANCER BY EARLY DETECTION OF CANCER THROUGH REGULAR MAMMOGRAM AND PAP TEST SCREENINGS AND TESTS FOR COLORECTAL CANCER, DIAGNOSTIC SERVICES, AND PROMPT ACCESS TO CANCER TREATMENT. SCCA ACCEPTS REFERRALS FOR BREAST HEALTH SERVICES FROM PHSKC WHEN THE PRIMARY CARE PHYSICIAN HAS DETECTED SOMETHING OF INTEREST. SCCA PERFORMS DIAGNOSTICS. IF THE PATIENTS ARE DEEMED TO HAVE CANCER, SCCA WILL TREAT THESE PATIENTS. SCCA ALSO HAS THE UNIQUE ABILITY TO HELP ENROLL PATIENTS INTO THE WBCCHP PROGRAM. ONCE IDENTIFIED BY SCCA, THEY ARE FAST TRACKED AT THE WASHINGTON STATE DEPARTMENT OF SOCIAL AND HEALTH SERVICES INTO WBCCHP. PATIENTS WHO COME TO SCCA DIRECTLY TO HAVE DIAGNOSTIC SERVICES COMPLETED AND CANCER IS FOUND, CAN BE ENROLLED DIRECTLY BY THE SCCA INTO THE WBCCHP. ENROLLMENT INTO WBCCHP IS DEPENDENT ON ELIGIBILITY CRITERIA. WBCCHP IS FUNDED BY THE CENTERS FOR DISEASE CONTROL AND PREVENTION, WASHINGTON STATE, AND PUGET SOUND AFFILIATE SUSAN G. KOMEN BREAST CANCER FOUNDATION.SEA MAR COMMUNITY HEALTH CENTER IS A COMMUNITY-BASED ORGANIZATION COMMITTED TO PROVIDING QUALITY, COMPREHENSIVE HEALTH, HUMAN, AND HOUSING SERVICES TO DIVERSE COMMUNITIES, SPECIALIZING IN SERVICE TO LATINOS. SEA MAR'S CLINICS ARE LOCATED IN ELEVEN COUNTIES IN WASHINGTON STATE. THE SCCA'S RELATIONSHIP WITH SEA MAR IS TO PROVIDE CLINICAL EDUCATION OPPORTUNITIES FOR PRIMARY CARE PROVIDERS IN THE AREAS OF EARLY DETECTION AND PREVENTION OF CANCER. ANOTHER ASPECT OF THE SEA MAR RELATIONSHIP IS TO FOSTER CONTINUITY OF CARE FOR SEA MAR PATIENTS WHO ARE DIAGNOSED WITH CANCER BETWEEN SEA MAR, SCCA, AND SCCA'S NETWORK MEMBERS. PART VI, LINE 5: SEATTLE CANCER CARE ALLIANCE (SCCA) IS A UNIQUE CONVERGENCE, COMBINING THE TALENTS AND RESOURCES OF THREE WORLD-RENOWNED INSTITUTIONS: FRED HUTCHINSON CANCER RESEARCH CENTER, SEATTLE CHILDREN'S, AND UW MEDICINE.TODAY, INNOVATION AT SCCA HAS REACHED AN EXTRAORDINARY VELOCITY, AS WE BUILD ON WHAT WE KNOW TO SAVE LIVES. OUR DOCTORS AND RESEARCHERS ARE DEVELOPING REVOLUTIONARY NEW THERAPIES, AND REFINING EVERY ASPECT OF PATIENT CARE TO MAKE IT SAFER, MORE EFFECTIVE, AND MORE PATIENT-FOCUSED. THESE ADVANCES ARE THE RESULT OF THOUGHTFUL CONVERGENCES IN BOTH THE LAB AND THE CLINIC.THIS EXCITING WORK IS TAKING PLACE IN PRE-CLINICAL RESEARCH IN GENOMICS AND MOLECULAR BIOLOGY. IT OCCURS IN SCCA'S MULTI-DISCIPLINARY CLINICS, WHERE DOCTORS WITH ALL RELEVANT SPECIALTIES FOCUS THEIR EXPERTISE ON EACH INDIVIDUAL PATIENT. WE'RE INTEGRATING NEW INITIATIVES IN PALLIATIVE CARE, INFECTION CONTROL, AND PERSONALIZED THERAPIES. OUR CLINICAL PATHWAYS MAP THESE CONVERGENCES TO UNIFY TREATMENT APPROACHES THROUGHOUT SCCA, OUR NETWORK, AND THE COMMUNITY.WHAT WE CALL 'CONVERGENCE' IS REMARKABLE AND ONGOING. WE'RE COMBINING OUR STRENGTHS TO HELP PATIENTS WIN SURVIVAL, AND DOING EVERYTHING WE CAN TO PROMOTE THEIR HEALTH, SAFETY, AND WELL-BEING.SCCA IS MORE EXCITED ABOUT THE PROGRESS WE ARE MAKING IN HELPING PATIENTS SURVIVE CANCER THAN AT ANY OTHER TIME IN SCCA'S HISTORY. NOT SINCE THE DAYS OF DON THOMAS' FIRST BONE MARROW TRANSPLANTATION HAVE WE SEEN ADVANCES WITH THIS MUCH POTENTIAL.THE AREA OF CLINICAL RESEARCH WE ARE SO ENTHUSIASTIC ABOUT IS IMMUNOTHERAPY. WE'RE STARTING TO REAP THE BENEFITS FROM THE CONVERGENCE OF TWO REVOLUTIONS IN BIOLOGY. SUCH MOMENTS ARE NOT COMMON IN THE HISTORY OF MANKIND, SO IT'S WORTH REFLECTING FOR A FEW MOMENTS ON THE MAGNITUDE OF THE PROGRESS THAT HAS OCCURRED IN JUST THE LAST DECADE.THE FIRST REVOLUTION STEMS FROM THE EXPONENTIAL RETURNS WE'VE RECEIVED FROM INVESTMENTS IN THE FIELD OF GENOMICS. IT WAS LESS THAN A DOZEN YEARS AGO, IN 2003, WHEN THE HUMAN GENOME PROJECT FIRST SEQUENCED THE ENTIRE HUMAN DNA CODE - ALL THREE BILLION BASE PAIRS. THAT EFFORT TOOK MORE THAN 10 YEARS AND $1 BILLION. TODAY, WE CAN DO THE SAME THING ONE MILLION TIMES MORE EFFICIENTLY. IN 2014 IT TOOK ONLY 10 DAYS TO SEQUENCE A PERSON'S ENTIRE GENOME, AT A COST OF LESS THAN $1,000.FOR MANY TYPES OF CANCER, DOCTORS IN OUR CLINICS CAN SEQUENCE THE DNA OF A PATIENT'S TUMOR TO IDENTIFY THE MUTATIONS THAT MAKE IT DIFFERENT FROM NORMAL TISSUE. BASED ON THIS INFORMATION, WE CAN SELECT THERAPIES THAT TARGET EACH PATIENT'S SPECIFIC GENETIC MUTATION. AS SUCH, ADVANCES IN GENOMICS ARE ALLOWING US TO MATCH TREATMENTS TO TUMORS WITH A LEVEL OF PRECISION UNIMAGINABLE A DECADE AGO.THE SECOND REVOLUTION IS IN OUR UNDERSTANDING OF THE HUMAN IMMUNE SYSTEM. AS YOU PROBABLY KNOW, THE IMMUNE SYSTEM HAS THE ABILITY TO SENSE INCURSIONS FROM COUNTLESS TYPES OF BACTERIA AND VIRUSES AND, WITHIN A FEW DAYS, CLEAR THEM FROM THE BODY. WHILE CANCER, LIKE BACTERIA AND VIRUSES, HAS DIFFERENCES FROM NORMAL CELLS THAT OUR IMMUNE SYSTEM SHOULD BE ABLE TO DETECT, PREVIOUS EFFORTS TO USE THE IMMUNE SYSTEM TO TREAT CANCER HAVE FAILED. TO ADDRESS THIS PROBLEM, WE'VE BEEN WORKING - SINCE THE DAYS OF THE FIRST BONE MARROW TRANSPLANTS - TO IDENTIFY THE MECHANISMS THAT ENABLE THE IMMUNE SYSTEM TO DO ITS JOB. INCREASINGLY, WE CAN IDENTIFY NOT ONLY WHAT FUNCTIONS SPECIFIC GENES CONTROL, BUT ALSO HOW GENES' SIGNALS ARE TRANSMITTED ALONG PRESCRIBED PATHWAYS VIA CHAINS OF PROTEINS.THE CONVERGENCE OF THESE TWO REVOLUTIONS - GENOMICS AND THE MOLECULAR BIOLOGY OF THE IMMUNE SYSTEM - HAS GIVEN BIRTH TO THE DISCIPLINE OF IMMUNOTHERAPY, WHERE WE ARE MAKING GIGANTIC STRIDES ALMOST ON A DAILY BASIS.IN IMMUNOTHERAPY TODAY, WE'VE REACHED THE POINT WHERE WE'RE ABLE TO TAKE IMMUNE CELLS FROM A PATIENT AND GENETICALLY MANIPULATE THEM BY ADDING AN ANTIBODY RECEPTOR THAT SEES THE CANCER. WE HARVEST THE PATIENT'S CELLS, PUT IN THE NECESSARY MACHINERY, RE-INFUSE THOSE T-CELLS INTO THE PATIENT, AND STAND BACK AND WATCH. WHAT WE SEE IS, IN MANY CASES, MIRACULOUS. AS ONE PATIENT PARTICIPATING IN A CLINICAL TRIAL OF THIS THERAPY FOR OTHERWISE UNTREATABLE LYMPHOMA SAID, "I COULD FEEL MY LYMPH NODES MELTING AWAY AS IF THEY WERE ICE CUBES."WE WROTE ABOUT THIS TREATMENT, CALLED CAR T-CELL THERAPY, IN LAST YEAR'S REPORT PUBLISHED ON OUR WEBSITE AT WWW.SEATTLECCA.ORG/SCCAQUICKFACTS.CFM. SINCE THEN, OUR RESEARCHERS HAVE MADE EXCITING PROGRESS. BASED ON THE LABORATORY WORK OF STANLEY RIDDELL, MD, THE CLINICAL TEAM, LED BY DR. MALONEY, MD, PHD AND CAMERON TURTLE, MD, PHD, HAS NOW TREATED NEARLY 30 PATIENTS WITH ACUTE LYMPHOCYTIC LEUKEMIA, AND WE ARE SEEING RAPID COMPLETE RESPONSES IN MANY CASES. THE RESULTS HAVE BEEN SO ENCOURAGING THAT WE ARE ACTIVELY PLANNING TO OPEN TRIALS OF CAR T-CELL THERAPY FOR OTHER CANCERS, INCLUDING SOLID TUMORS SUCH AS BREAST AND LUNG CANCER.CONVERGENCES ARE ALSO OCCURRING IN OTHER TYPES OF IMMUNOTHERAPY - FOR EXAMPLE, A RECENT INITIATIVE THAT COMBINES TIL THERAPY WITH THE USE OF TARGETED CHECKPOINT INHIBITORS. TIL (SHORT FOR TUMOR-INFILTRATING LYMPHOCYTES) IS A T-CELL THERAPY THAT WE'VE USED SUCCESSFULLY AGAINST MELANOMA. IT INVOLVES SELECTING T-CELLS THAT WORK BEST IN FIGHTING THE PATIENT'S SPECIFIC TUMOR, GROWING THEM IN LARGE NUMBERS, AND REINFUSING THEM. SOME TUMORS HAVE A RECEPTOR, PD-1, WHICH TURNS OFF T-CELLS. WORKERS AT FRED HUTCH CONTRIBUTED TO THE DEVELOPMENT OF AN ANTIBODY TO PD-1, KEYTRUDA, WHICH RECENTLY RECEIVED FDA APPROVAL FOR THE TREATMENT OF MELANOMA. NOW, SYLVIA LEE, MD IS COMBINING TIL WITH KEYTRUDA, BASED ON THE HYPOTHESIS THAT THE TWO SHOULD WORK WELL TOGETHER. IF THE TWO THERAPIES PROVE TO HAVE AS SYNERGISTIC EFFECTS AS WE EXPECT, DR. LEE WILL EXPAND TRIALS TO OTHER CANCERS IN ADDITION TO MELANOMA.BASED ON ALL THE REMARKABLE PROGRESS WE'RE SEEING AT SCCA, WE ARE ABSOLUTELY CONVINCED THAT, IN FIVE YEARS, HALF OF OUR PATIENTS WHO HAVE METASTATIC DISEASE WILL BE TREATED WITH IMMUNOTHERAPY. IT WILL BECOME A MAINSTAY, PERHAPS DIMINISHING THE NEED FOR TRADITIONAL MORE TOXIC THERAPIES.AT SCCA, WE'RE CONSTANTLY SEEKING TO ADVANCE THE STANDARD OF CARE, BOTH THROUGH INNOVATION AND BY FINE-TUNING THE QUALITY OF OUR PATIENT CARE. THAT'S WHY WE PLACE SO MUCH EMPHASIS ON PROVIDING PATIENTS WITH ACCESS TO CLINICAL TRIALS: THESE STUDIES COMPARE THE CURRENT FDA-APPROVED STANDARD TO NEW APPROACHES THAT WE HOPE WILL BE EVEN BETTER. AND, IN MANY CASES WHERE THERE IS NO THERAPY AVAILABLE, WE PROVIDE PATIENTS WITH ACCESS TO THE MOST PROMISING TREATMENT UNDER INVESTIGATION.WE FOCUS ON QUALITY AS WE MONITOR, MEASURE, ANALYZE, AND IMPROVE OUR PROTOCOLS. AND, WHILE ALL ASPECTS OF CARE ARE IMPORTANT, THE QUALITY MEASURE THAT MOST MATTERS TO THE MAJORITY OF OUR PATIENTS IS, QUITE SIMPLY, SURVIVAL. DOES GETTING TREATED AT SCCA TRULY MAKE A DIFFERENCE IN THEIR CHANCES OF SURVIVING CANCER?THE DATA SHOW THAT THE ANSWER IS A DEFINITIVE "YES." EVERY YEAR SCCA PUBLISHED AN ANNUAL REPORT, WE'VE INCLUDED FIVE-YEAR SURVIVAL STATISTICS THAT COMPARE OUR PATIENTS' OUTCOMES TO THOSE OF OTHER CANCER HOSPITALS AND MEDICAL CENTERS ACROSS THE U.S. SINCE 2002, WHEN THESE DATA WERE FIRST COLLECTED, WE HAVE BEEN CLEARLY AMONG THE BEST PLACES FOR PATIENTS TO BE TREATED. BETTER STILL, WE'VE SHOWN CONTINUOUS IMPROVEMENT EVERY YEAR SINCE THEN.HOW DOES SCCA ACHIEVE THESE RESULTS? BY MAINTAINING A MINDSET THAT THERE IS NO DETAIL TOO SMALL WHEN IT COMES TO THE HEALTH OF OUR PATIENTS. ONE EXAMPLE IS OUR DEDICATED INFECTION CONTROL GROUP, LED BY STEVE PERGAM, MD, MPH, WHO STRIVE TO ENSURE THAT OUR PATIENTS DON'T GET ADDITIONAL INFECTIONS THAT COULD COMPLICATE THEIR TREATMENT. THIS IS AN AREA WHERE SCCA STANDS TALL: OUR INFECTION RATES ARE SUBSTANTIALLY LOWER AND, IN FACT, OUR OWN SARA PODCZERVINSKI, RN, MPH, CIC, WAS ONE OF SIX WINNERS, WORLDWIDE, OF THE HEROES OF INFECTION PREVENTION AWARD FOR 2014.WE ALSO TRY TO DO AS MUCH AS WE CAN TO HELP PATIENTS AFTER THEY COMPLETE TREATMENT AT SCCA - AND ELSEWHERE. IT'S ESTIMATED THAT THERE ARE APPROXIMATELY 125,000 CANCER SURVIVORS IN WASHINGTON STATE ALONE. THESE PEOPLE ARE COPING WITH THE SIDE EFFECTS OF THEIR TREATMENT AS WELL AS THE RISK OF RECURRENCE. UNDER THE DIRECTION OF SCOTT BAKER, MD, MS, AND KAREN SYRJALA, PHD, THE SCCA SURVIVORSHIP CLINIC PROVIDES PATIENTS WITH A PERSONALIZED SURVIVORSHIP CARE PLAN THAT DETAILS ALL OF THEIR PAST TEST RESULTS AND TREATMENTS AND SUGGESTS STRATEGIES FOR ONGOING HEALTH MAINTENANCE.EVERYTHING WE DO AT SCCA CONVERGES ON SURVIVORSHIP. FROM PRE-CLINICAL RESEARCH, THROUGH CLINICAL TRIALS AND QUALITY CONTROL, TO POST-TREATMENT FOLLOW-UP, EVERYONE HERE FOCUSES ON DELIVERING SUCCESSFUL OUTCOMES FOR OUR PATIENTS, THEIR FRIENDS AND FAMILIES, AND OUR COMMUNITY. PART VI, LINE 6: SCCA IS NOT PART OF AN AFFILIATED HEALTH CARE SYSTEM. PART VI, LINE 7: WASHINGTON STATE REQUIRES THE SCCA TO HAVE ITS CHNA INFORMATION AVAILABLE ON ITS WEBSITE 15 DAYS FOLLOWING THE FILING OF ITS 990 WITH THE IRS. ALSO, WASHINGTON STATE HAS IMPLEMENTED ITS OWN COMPENSATION REPORTING REQUIREMENTS WHICH CAN BE THE IRS FORM 990 SCHEDULE J OR USE OF THE WASHINGTON FORM. SCCA HAS COMPLIED WITH THE COMPENSATION REPORTING REQUIREMENTS AND HAS COMPLIED WITH THE ADDITIONAL CHNA REPORTING REQUIREMENTS. 1 UNIVERSITY OF WASHINGTON FOUNDATION PO BOX 358045 SEATTLE WA 98195 943079432 501(C)(3) 321104 N/A N/A TO SUPPORT UNIVERSITY OF WASHINGTON FOUNDATION EVENTS. FRED HUTCHINSON CANCER RESEARCH CENTER 1100 FAIRVIEW AVE N SEATTLE WA 98109 237156071 501(C)(3) 191677 N/A N/A TO FUND RESEARCH SPECIFIC TO CANCER RESEARCH ACTIVITIES. UNIVERSITY OF WASHINGTON PHYSICIANS PO BOX 34115 SEATTLE WA 98124 911220843 501(C)(3) 16920 N/A N/A UWP ACCEPTS A GREATLY REDUCED FEE FOR SERVICE AS PART OF EFFORTS TO SCREEN THE UNDERSERVED THROUGH THE MAMMOVAN PROGRAM. STARBUCKS CYCLING 21527 NE 9TH PL SAMMAMISH WA 98074 274072470 501(C)(3) 15000 N/A N/A TO SUPPORT RACING TEAMS WHILE ALSO SUPPORTING LOCAL COMMUNITIES. EVERGREENHEALTH FOUNDATION 12040 NE 128TH ST MS-5 KIRKLAND WA 98034 911519430 501(C)(3) 8000 N/A N/A TO SUPPORT EVERGREENHEALTH FOUNDATION'S ACUTE REHABILITATION UNIT, SUPPORTING A HIGHLY SKILLED TEAM OF PROFESSIONALS WHO HELP PATIENTS PREPARE FOR THE TRANSITION HOME FOLLOWING A SERIOUS ILLNESS, INJURY, OR HOSPITALIZATION THAT HAS LED TO IMPAIRED FUNCTION. 5 1 CASH FOR EMERGENCIES (ONE TIME ASSISTANCE PROGRAM) 28 8357 N/A N/A FUNERAL/MEMORIAL SERVICES 3 1151 N/A N/A TRANSPORTATION 113 12556 N/A N/A FOOD 1323 82930 2807 FMV GIFT CARDS PROVIDED TO PATIENTS FOR FOOD AND GROCERY STORES. SHELTER 305 86285 121972 FMV RENTS PAID FOR PATIENTS. MEDICAL 2 846 N/A N/A PARKING 25 15420 N/A N/A SUNDRIES 747 6663 6375 FMV BOOKS, DVDS, CDS, MAGAZINES, BAGS, TOYS, BLANKETS & OTHERS. UTILITIES 14 3377 N/A N/A WIGS 523 2224 44942 FMV WIGS & HATS FOR CANCER PATIENTS. MEDICAL ACCESSORIES 261 0 7403 FMV MEDICAL ACCESSORIES INCLUDING PARTS & SUPPLIES FOR PROSTHESIS. TICKETS 6737 0 278468 FMV EVENT TICKETS TO SPORTS GAMES, ART PERFORMANCES, AND LOCAL ATTRACTIONS. STEINBERG TUITION ASSISTANCE 4 33025 N/A N/A PEGGY MEANS SCHOLARSHIP 3 4500 N/A N/A PART I, LINE 2: WITH REGARD TO GRANTS TO ORGANIZATIONS REPORTED ON SCHEDULE I, PART II, THE SCCA VERIFIES THE GRANTEES ARE QUALIFIED 501(C)(3) ORGANIZATIONS WITH A MISSION COMPATIBLE WITH THAT OF SCCA. THE SCCA RELIES ON THE GRANTEE ORGANIZATION MAINTAINING ITS TAX EXEMPT STATUS WITH THE IRS AND DOES NOT IMPOSE THE BURDEN OF REPORTING BACK TO SCCA AS TO THE EXPENDITURE OF GRANT FUNDS. WITH REGARD TO GRANTS OR OTHER ASSISTANCE TO INDIVIDUALS REPORTED ON SCHEDULE I, PART III, MOST OF THE REQUESTS FOR ASSISTANCE ARE MADE THROUGH PATIENT FAMILY SERVICES. THESE REQUESTS ARE CONSIDERED IN ACCORDANCE WITH A MODIFICATION TO SCCA'S CHARITY CARE POLICY. ASSISTANCE IS PROVIDED IN RESPONSE TO SPECIFIC NEEDS OF INDIVIDUALS FOR INTENDED PURPOSES BY PAYING FOR CERTAIN ASSISTANCE DIRECTLY ON BEHALF OF THE INDIVIDUAL. ALSO, PATIENT FAMILY SERVICES MAINTAINS CONTACT WITH PATIENTS RECEIVING ASSISTANCE THROUGHOUT THEIR TREATMENT AT SCCA. WITH REGARD TO SCHOLARSHIPS GIVEN, AN APPLICATION IS MADE AND REVIEWED BY THE SENIOR MANAGEMENT STAFF. VERY SPECIFIC CRITERIA ARE REQUIRED. ONLY BONA FIDE TUITION AND FEES QUALIFY FOR FUNDING. X 1 1 X X X X 0 0 0 0 0 0 0 0 0 FRED APPELBAUM MD EXECUTIVE DIRECTOR/PRESIDENT 293262 0 29000 0 0 0 0 0 0 0 322262 0 0 0 NORMAN HUBBARD EXECUTIVE VICE PRESIDENT 512146 0 63440 0 0 0 32565 0 15385 0 623536 0 0 0 JONATHAN TINGSTAD VP/CFO 392111 0 36075 0 0 0 32565 0 20023 0 480774 0 0 0 MADELINE BUELT VP OPERATIONS/CHIEF NURSE 328566 0 19176 0 0 0 32565 0 16297 0 396604 0 0 0 F MARC STEWART MD VP/MEDICAL DIRECTOR 408220 0 23000 0 0 0 0 0 0 0 431220 0 0 0 DAVID ACKERSON VP/CHIEF INFO OFFICER 327661 0 30030 0 0 0 32565 0 10397 0 400653 0 0 0 DEBORAH GENTZEN VP/CHIEF STRATEGY OFFICER 355218 0 32858 0 0 0 32565 0 19799 0 440440 0 0 0 BARBARA JAGELS VP/QUALITY SAFETY AND VALUE 149777 0 9367 0 0 0 14513 0 17927 0 191584 0 0 0 GRETCHEN HANNA DIR. CORPORATE FINANCE 208662 0 13000 0 0 0 21341 0 12834 0 255837 0 0 0 CHERYL WYMAN DIR. DIAGNOSIS THERAPY SVCS 207414 0 13055 0 0 0 21424 0 15103 0 256996 0 0 0 JOSEPH NORTON DIRECTOR OF FINANCE 204845 0 9750 0 0 0 19274 0 18491 0 252360 0 0 0 ZAKARIA RAMADAN-JRADI DIR. CELL THRPY & CLIN LAB 199395 0 9953 0 0 0 18596 0 18398 0 246342 0 0 0 ALEANA WAITE DIR. RES INTEG, IMMUNO, CELL THRPY 179313 0 11716 0 0 0 17749 0 14546 0 223324 0 0 0 KRISTINE LOGAN DIRECTOR PT ACCESS & FACILITIES 174158 0 10043 0 0 0 16010 0 8847 0 209058 0 0 0 SUSAN HAMMOND DIRECTOR PROGRAM MANAGEMENT 172183 0 10725 0 0 0 16604 0 14695 0 214207 0 0 0 LINDA LAKE DIR. CLIN INFO SYST & HIM 166467 0 10123 0 0 0 15355 0 8797 0 200742 0 0 0 ALPHONSO EMERY DIR. DIVERSITY EFFORTS 164164 0 7517 0 0 0 13247 0 8722 0 193650 0 0 0 MOREEN DUDLEY DIR. SUPPORT CARE/SPEC CLINICS 154533 0 9708 0 0 0 14701 0 12503 0 191445 0 0 0 CAMILLE RAPACZ DIRECTOR CPI 150554 0 9546 0 0 0 14155 0 14186 0 188441 0 0 0 SHARI MCCLURE DIR. MEDICAL STAFF SERVICES 145899 0 8620 0 0 0 12981 0 8502 0 176002 0 0 0 MICHELLE HALL DIRECTOR OF IT SERVICES 141542 0 8950 0 0 0 12916 0 14086 0 177494 0 0 0 DONNA LENDERMAN REGISTERED NURSE 179992 0 0 0 0 0 15572 0 4321 0 199885 0 0 0 MARGARET OWENS CTP QUALITY SENIOR MANAGER 169237 0 0 0 0 0 14406 0 1777 0 185420 0 0 0 KAREN HOLLOWAY RADIATION ONCOLOGY MANAGER 143372 0 0 0 0 0 11879 0 8552 0 163803 0 0 0 CLAIRE BECK-KEELER DIRECTOR OF MARKETING 133950 0 8788 0 0 0 12415 0 17788 0 172941 0 0 0 CECILIA ZAPATA DIR. REGIONAL GLOBAL NETWORK 134161 0 8372 0 0 0 11715 0 8503 0 162751 0 0 0 PART I, LINE 1A SCCA LEADERSHIP TEAM HAS MEMBERSHIPS AT LOCAL CLUBS TO ENABLE MEETINGS AND RECRUITMENT TO TAKE PLACE. NORMAN HUBBARD, MARC STEWART, AND JONATHAN TINGSTAND RECEIVE THESE BENEFITS. SCCA HAS A DETAILED EXPENSE REIMBURSEMENT POLICY FOR TRAVEL AND ENTERTAINMENT. THE HEALTH/SOCIAL CLUB DUES ARE NOT SPECIFICALLY INCLUDED IN THE WRITTEN POLICY. SCCA REIMBURSES FOR THESE EXPENSES SUBJECT TO THE TERMS OF THE OVERALL POLICY. ANY PAYMENTS WHICH ARE A TAXABLE FRINGE BENEFIT ARE INCLUDED IN THE TAXABLE INCOME REPORTABLE ON FORM W-2 FOR THE RECIPIENT. ALL RELATED CORPORATE EXPENSES ARE MONITORED BY THE AP SUPERVISOR FOR PERSONAL/BUSINESS USE FOR COMPLIANCE WITH THE ACCOUNTABLE PLAN AND REIMBURSEMENT POLICY. SCHEDULE J, PART II: FRED APPELBAUM, MD RECEIVED COMPENSATION OF $322,262 FROM FRED HUTCHINSON CANCER RESEARCH CENTER, AN UNRELATED ORGANIZATION FOR SERVICES PROVIDED TO SEATTLE CANCER CARE ALLIANCE. F. MARC STEWART, MD RECEIVED COMPENSATION OF $431,220 FROM FRED HUTCHINSON CANCER RESEARCH CENTER, AN UNRELATED ORGANIZATION FOR SERVICES PROVIDED TO SEATTLE CANCER CARE ALLIANCE. A WASHINGTON HEALTH CARE FACILITIES AUTHORITY 911108929 93978E2C5 2009-02-03 87819178 CAPITAL ACQUISITION, REFINANCE OLD DEBT ISSUED 3/6/2001 0 0 0 B WASHINGTON HEALTH CARE FACILITIES AUTHORITY 911108929 2010-11-18 21415000 TO REFUND 2008 WEEKLY RATE BONDS 0 0 0 A 6645000 87819178 7392293 1671200 35272376 43483521 2010 1 0 1 1 B 1598000 21415000 325000 21090000 2009 0 0 1 1 A 0 0 0 1 1 0.00540 0.00000 0.00540 0 0 1 B 0 0 0 0 0.00000 0.00000 0.00000 0 0 1 A 0 0 0 1 0 0 0 0 1 B 0 0 0 0 1 0 0 0 1 A 1 B 1 DATE REBATE COMPUTATION PERFORMED ISSUER NAME: WASHINGTON HEALTH CARE FACILITIES AUTHORITY DATE THE REBATE COMPUTATION WAS PERFORMED: 02/03/2014 PART III, LINE 4, COLUMN A THE PERCENTAGE REPORTED ON LINE 4 REPRESENTS THE PERCENTAGE OF RESEARCH REVENUE FROM BOTH GOVERNMENTAL AND INDUSTRY SPONSORED RESEARCH. GOVERNMENT SPONSORED RESEARCH FALLS INTO A PRIVATE BUSINESS USE SAFE HARBOR, INDUSTRY SPONSORED DOES NOT. BECAUSE THE COMBINED REVENUE FROM THE GOVERNMENT AND PRIVATELY SPONSORED RESEARCH IS LESS THAN THE APPLICABLE THRESHOLD, SCCA HAS ELECTED NOT TO DEVOTE THE RESOURCES REQUIRED TO ALLOCATE THE AGGREGATE RESEARCH REVENUE BETWEEN GOVERNMENT AND PRIVATELY SPONSORED RESEARCH. AS SUCH, PRIVATE BUSINESS USE DUE TO RESEARCH IS OVERSTATED. SCCA DOES NOT HAVE DIRECT CONTRACTS WITH INDUSTRY SPONSORED CORPORATIONS. SCCA PERFORMS SERVICES PRIMARILY FOR UNIVERSITY OF WASHINGTON, A GOVERNMENTAL ENTITY, AND FRED HUTCHINSON CANCER RESEARCH CENTER, A 501(C)(3) ENTITY. UNIVERSITY OF WASHINGTON AND FRED HUTCHINSON CANCER RESEARCH CENTER ARE CONDUCTING THE RESEARCH AND HAVE THE DIRECT CONTRACTS WITH THE GOVERNMENT AND PRIVATE INDUSTRY SPONSORED RESEARCH. SEATTLE PROCURE MANAGEMENT LLC SEE BELOW. 1324314 PAYMENT FOR SERVICES. RELATIONSHIP BETWEEN INTERESTED PERSON AND ORGANIZATION: SHARED BOARD MEMBER AND OFFICERS. TWO SCCA OFFICERS AND ONE SCCA BOARD MEMBER ARE BOARD MEMBERS OF PROCURE SEATTLE HOLDINGS, LLC, WHICH IS THE 100% OWNER OF SEATTLE PROCURE MANAGEMENT, LLC. 0 X 2 667 SELLING PRICE X 6375 SELLING PRICE X 392 2807 SELLING PRICE X 261 7403 SELLING PRICE X EVENT TICKETS 6712 278468 SELLING PRICE X HATS/WIGS 520 44942 SELLING PRICE X FURNITURE 5 1800 SELLING PRICE 0 0 1 0 PART I, COLUMN (B): THE NUMBER OF ITEMS RECEIVED WAS USED TO DETERMINE THE AMOUNTS IN COLUMN B. FORM 990, PART I, LINE 6: THE VOLUNTEERS OFFER DIRECT SUPPORT IN SOCIAL, EMOTIONAL, AND PRACTICAL WAYS TO CONNECT WITH PATIENTS AND FAMILIES THROUGHOUT EACH PHASE OF A PATIENT'S EXPERIENCE WITH SCCA. THE SCCA HAS 20 VOLUNTEER ROLES: BREAST CENTER, CHILD LIFE, DRIVERS, EVENTS COMMITTEE, HUTCH SCHOOL, RAIN OR SHINE, GUEST SERVICES, WIG FITTER, SCCA HOUSE KITCHEN HOST, SPECIAL EVENTS, PATIENT EDUCATION, SHINE, COSMETOLOGY/BARBER, WOMEN'S CENTER LOBBY, SCCA HOUSE CONCIERGE, PATIENT/FAMILY SERVICES, PHYSICAL THERAPY, COMFORT MASSAGE, HEALING MUSIC, GENERAL ONCOLOGY LOBBY. THE 18 MEMBERS OF THE BOARD ALSO SERVE AS VOLUNTEERS. FORM 990, PART VI, SECTION A, LINE 2 MARK GROUDINE, RICH MCCUNE, MYRA TANITA, AND FRED APPELBAUM HAVE BUSINESS RELATIONSHIPS. EACH NAMED INDIVIDUAL SERVES AS A SCCA BOARD MEMBER OR OFFICER, AND THESE INDIVIDUALS ARE ALSO CURRENT BOARD MEMBERS, OFFICERS, DIRECTORS, OR KEY EMPLOYEES OF ANOTHER ORGANIZATION. ROBB BAKEMEIER, LISA BRANDENBURG, MIKE DELMAN, AND BRUDER STAPLETON HAVE BUSINESS RELATIONSHIPS. EACH NAMED INDIVIDUAL SERVES AS A SCCA BOARD MEMBER, AND THESE INDIVIDUALS ARE ALSO BOARD MEMBERS, OFFICERS, DIRECTORS OR KEY EMPLOYEES OF ANOTHER ORGANIZATION. FORM 990, PART VI, SECTION A, LINE 6 SCCA HAS THREE MEMBERS. MEMBERS MUST BE GOVERNMENTAL ENTITIES OR ORGANIZATIONS EXEMPT UNDER IRC SECTION 501(C)(3). EACH MEMBER CURRENTLY HAS A 33 1/3% VOTING INTEREST. NO NEW MEMBER MAY BE ADMITTED TO THE CORPORATION WITHOUT THE APPROVAL OF EXISTING MEMBERS HOLDING AGGREGATE VOTING INTERESTS OF AT LEAST 75%. FORM 990, PART VI, SECTION A, LINE 7A EACH MEMBER WILL APPOINT SIX MEMBERS OF THE EIGHTEEN DIRECTORS OF THE ORGANIZATION. FORM 990, PART VI, SECTION A, LINE 7B THE BOARD OF DIRECTORS OF THE CORPORATION MAY NOT, EXCEPT BY AFFIRMATIVE VOTE OF 75% OF THE DIRECTORS IN OFFICE AND WITH THE APPROVAL OF THE MEMBERS HOLDING AGGREGATE VOTING INTERESTS OF AT LEAST 75%: (A) AMEND, ALTER OR REPEAL CERTAIN SECTIONS OF THE CORPORATION'S BYLAWS; (B) REMOVE ANY DIRECTOR OR THE CHAIR OF THE CORPORATION; PROVIDED THAT A MEMBER MAY REMOVE A DIRECTOR APPOINTED BY SUCH MEMBER AT ANY TIME; (C) AMEND THE ARTICLES OF INCORPORATION OF THE CORPORATION; (D) ADOPT A PLAN OF MERGER OR CONSOLIDATION WITH ANOTHER CORPORATION; (E) AUTHORIZE THE SALE, LEASE, OR EXCHANGE (OR PLEDGING AS SECURITY) OF ALL OR SUBSTANTIALLY ALL OF THE PROPERTY AND ASSETS OF THE CORPORATION OR ANY ASSET NOT IN THE ORDINARY COURSE OF BUSINESS; (F) AUTHORIZE THE VOLUNTARY DISSOLUTION OF THE CORPORATION OR REVOKE PROCEEDINGS THEREFOR; (G) ADOPT A PLAN FOR THE DISTRIBUTION OF THE ASSETS OF THE CORPORATION; (H) AMEND, ALTER, OR REPEAL ANY RESOLUTION OF THE MEMBERS OF THE CORPORATION; (I) INITIATE OR RESOLVE LITIGATION IN WHICH THE CORPORATION IS A PARTY IF THE LITIGATION OR RESOLUTION WOULD HAVE A MATERIAL ADVERSE EFFECT ON THE FINANCIAL WELL-BEING OR PUBLIC PERCEPTION OF THE CORPORATION OR ITS MEMBERS; (J) CHANGE THE FUNDAMENTAL PURPOSES OF THE CORPORATION; (K) ENTER INTO ANY NEW LINE OF BUSINESS; (L) OR AUTHORIZE THE RELOCATION FROM THE UNIVERSITY OF WASHINGTON MEDICAL CENTER TO ANOTHER HOSPITAL FACILITY OF THE TWENTY INPATIENT BEDS FOR WHICH THE CORPORATION HAS BEEN GRANTED A HOSPITAL LICENSE. FINALLY, THE FOLLOWING IS SUBJECT TO APPROVAL BY THE CORPORATION'S MEMBERS: - THE CORPORATION'S ANNUAL BUDGET - APPOINTMENT OF THREE ADDITIONAL DIRECTORS TO THE BOARD EXECUTIVE COMMITTEE (IN ADDITION TO THE CORPORATION'S CHAIR, IMMEDIATE PAST CHAIR, VICE CHAIR, TREASURER, AND SECRETARY) - APPOINTMENT OF DIRECTORS TO THE BOARD GOVERNANCE COMMITTEE - APPOINTMENT OF TWO DIRECTORS TO THE BOARD FINANCE COMMITTEE (IN ADDITION TO THE TREASURER) - SELECTION OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS TO CONDUCT AN ANNUAL FINANCIAL AUDIT OF THE CORPORATION FORM 990, PART VI, SECTION B, LINE 11 THE FORM 990 WAS PREPARED BY A PUBLIC ACCOUNTING FIRM AND INTERNALLY REVIEWED PRIOR TO PRESENTATION TO THE BOARD-APPOINTED FINANCE AND AUDIT COMMITTEE. THE FORM 990 WAS PROVIDED TO THE FINANCE AND AUDIT COMMITTEE FOR REVIEW BEFORE FILING. THE CHAIR OF THE FINANCE AND AUDIT COMMITTEE REPORTS TO THE FULL BOARD. ALL BOARD MEMBERS ARE PRESENTED WITH A COPY BEFORE FILING FORM 990. FORM 990, PART VI, SECTION B, LINE 12C THE CONFLICT OF INTEREST POLICY IS ANNUALLY MONITORED THROUGH A QUESTIONNAIRE. IT IS A POLICY OF THE SCCA FOR SELF REPORTING. THIS SELF REPORTING IS APPLICABLE TO THE BOARD OF DIRECTORS AND ALL MANAGEMENT STAFF. THE DETERMINATION OF WHETHER AN ISSUE EXISTS IS MADE BY THE INTEGRITY OFFICER. THE ESCALATION PROCESS IS TO THE SENIOR MANAGEMENT TEAM, AND, IF DEEMED APPROPRIATE, TO THE BOARD OF DIRECTORS INTEGRITY COMMITTEE, BOARD OF DIRECTORS GOVERNANCE COMMITTEE, AND LEGAL COUNSEL. CONFLICTS OF INTEREST ARE ADDRESSED IF AND WHEN THEY ARISE. THE CONFLICTED BOARD MEMBER RECUSES HIM OR HERSELF FROM DISCUSSION AND VOTING ON THE MATTER. FORM 990, PART VI, SECTION B, LINE 15 AN INDEPENDENT COMPENSATION CONSULTING FIRM PERFORMS A MARKET ANALYSIS OF EXECUTIVE PAY AT COMPARABLE ORGANIZATIONS. A CONSULTANT FROM THIS FIRM PRESENTS ITS FINDINGS TO THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS EVERY TWO YEARS. THE ANALYSIS WAS LAST PERFORMED AND PRESENTED IN NOVEMBER 2013. IN THE INTERVENING YEARS, THE PRIOR YEAR'S MARKET ANALYSIS IS UPDATED USING AN APPROPRIATE INFLATION FACTOR FOR USE BY THE COMPENSATION COMMITTEE IN ITS ANNUAL REVIEW OF TOTAL COMPENSATION FOR THE OFFICERS. THE COMPENSATION COMMITTEE DOCUMENTS ITS MEETINGS AND DECISIONS IN A TIMELY MANNER. THE COMPENSATION COMMITTEE PROMPTLY REPORTS TO THE BOARD ALL ACTIONS TAKEN AND SIGNIFICANT ISSUES DISCUSSED AT ITS MEETINGS. FORM 990, PART VI, SECTION C, LINE 19 THE SCCA DOES NOT MAKE ITS GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY AVAILABLE TO THE PUBLIC. AS REQUIRED BY THE IRS, THE SCCA'S AUDITED FINANCIAL STATEMENTS ARE ATTACHED TO FORM 990, WHICH IS A PUBLIC DISCLOSURE DOCUMENT. FORM 990, PART IX, LINE 11G AISA INPATIENT SERVICES: PROGRAM SERVICE EXPENSES 40,126,394. MANAGEMENT AND GENERAL EXPENSES 771,516. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 40,897,910. INFO TECH & ADMIN SERVICES: PROGRAM SERVICE EXPENSES 955,706. MANAGEMENT AND GENERAL EXPENSES 1,408,401. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 2,364,107. LAB SERVICES: PROGRAM SERVICE EXPENSES 10,165,787. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 10,165,787. OTHER AGREEMENTS: PROGRAM SERVICE EXPENSES 622,016. MANAGEMENT AND GENERAL EXPENSES 75,000. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 697,016. CLINIC SERVICES: PROGRAM SERVICE EXPENSES 6,442,464. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 6,442,464. MEDICAL LEADERSHIP & FACULTY SUPPORT: PROGRAM SERVICE EXPENSES 17,423,787. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 17,423,787. FORM 990, PART XI, LINE 9: IMPAIRMENT LOSS -54,632.